If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
487
results.
Updated on
13/11/2026 [07:35:00]
Absstract of: US20260355311A1
Embodiments described herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, and pomalidomide, to the subject to treat the multiple myeloma.
Absstract of: AU2025260405A1
Disclosed herein are 4,6-substituted-2-(3'-1,1'-biphenyl-4-yl)quinoline analogs and pharmaceutically acceptable salts thereof that are inhibitors of dihydroorotate dehydrogenase (DHODH) with properties, including stability and bioavailability as disclosed herein. Also disclosed herein are methods of making the analogs and salts thereof. The disclosed analogs and salts thereof can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation.
Absstract of: US20260356912A1
Provided are a chimeric antigen receptor, and a GPRC5D antibody-containing chimeric antigen receptor and use thereof. The chimeric antigen receptor includes: an extracellular domain, capable of binding to a tumor antigen; a transmembrane domain, linked to the extracellular domain, the transmembrane domain being from a type I transmembrane protein or is an artificially synthesized transmembrane protein with a hydrophobic helix; and an intracellular domain, linked to the transmembrane domain. The tumor antigen is a tumor-specific antigen or a tumor-associated antigen. The amino acid sequence of the transmembrane domain is optimized, thereby providing the chimeric antigen receptor containing the GPRC5D antibody and an engineered immune cell. The engineered immune cell obtained based on the GPRC5D antibody exhibits a specific killing activity against multiple myeloma.
Absstract of: US20260356950A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a GPRC5DxCD3 bispecific antibody on a monthly dosing schedule.
Absstract of: US20260356970A1
The present disclosure provides antibodies, antigen binding fragments thereof, and fusion proteins, including chimeric antigen receptors, that target EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2). Also provided herein are methods of using such antibodies, antigen binding fragments thereof, and fusion proteins, for treating hematopoietic malignancies or hematological diseases (e.g., acute myeloid leukemia, myelodysplastic syndrome).
Absstract of: US20260356961A1
The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.
Absstract of: AU2026257525A1
Abstract The present disclosure relates to the use of 1-4-bromo-5-1-ethyl-7-(methylamino)-2-oxo- 1,2-dihydro-1,6-naphthyridin-3-yl-2-fluorophenyl-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo- 1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia- associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma. ct b s t r a c t c t
Absstract of: US20260357267A1
The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as β-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
Absstract of: EP4837911A1
Disclosed in the present invention are three crystal forms of thienopyrimidine compound A and a preparation method therefor, wherein crystal form I is of a trihydrochloride salt, and crystal form II and III are of dihydrochloride salts. The three crystal forms all have good stability and solubility, with a solubility of ≥4 mg/mL in a 5% aqueous glucose solution, so that the basic requirements for the solubility of a compound to be prepared into a lyophilized preparation for injection are met. The three crystal forms of thienopyrimidine compound A prepared in the present invention have good stability and solubility, can be prepared into a lyophilized preparation for clinical injection, and can be used for the effective treatment of patients with advanced, recurrent, etc. lymphoma, myeloma and lymphocytic leukemia, or drug-resistant patients.
Absstract of: WO2026227249A1
Provided are a culture medium and a culture method for culturing human primary B-cell lymphoma cells. The culture medium for culturing human primary B-cell lymphoma cells comprises an anti-immunoglobulin M antibody, a recombinant human CD40 ligand, CpG oligodeoxynucleotide 2006, superoxide dismutase, interleukin-2, interleukin-21, and interleukin-4. Also provided are B-cell lymphoma cells obtained by in vitro culturing using the culture medium, and a method and the use thereof in the efficacy evaluation and screening of drugs.
Absstract of: WO2026229443A1
The invention relates to a composition or a kit comprising a Toll-like receptor agonist and an Interleukin-7 (IL-7) antagonist as well as methods and uses for treating or preventing lymphoblastic leukemia.
Absstract of: WO2026228549A1
The present invention relates to an antigen-binding molecule that specifically binds to CD38, a conjugate comprising same, and the medical use thereof. Specifically, the present invention relates to an antibody-drug conjugate that specifically binds to CD38 and the use thereof in a drug for treating multiple myeloma.
Absstract of: US20260350412A1
Methods of speeding the training of a convolutional neural network (CNN) to classify new images of biological cells captured by an imaging flow cytometer (IFC) are disclosed. Transfer learning with and without mapping is used based on the selection of pre-trained CNN to be used. New images of biological cells can be classified with new classes that are provided such as classes for red blood cells and classes for DNA damage of lymphoma biological cells.
Absstract of: WO2026231609A1
Provided herein are methods of treating certain B cell lymphomas comprising administering a T-cell engager (TCE) in combination with 3-(6-(((3R,4R)-1-(5-chloro-4-((1-methyl-2-oxoindolin-5-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-yl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt thereof.
Absstract of: US20260347775A1
Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes and marrow infiltrating lymphocytes, from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and uses of such expanded TILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Absstract of: US20260345486A1
0000 An improved method of treating cancers CD19 CAR T cells by administering the CD19 CAR T cells to the central nervous system, e.g., by intracerebroventricular administration, is described.
Absstract of: US20260347354A1
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
Absstract of: US20260347349A1
0000 CXCR4 antagonists and pharmaceutical formulations thereof are disclosed. The compounds and pharmaceutical formulations disclosed herein can be used to antagonize the CXCR4 pathway for mobilizing stem cells or treating a condition, disorder, or disease associated with the CXCR4 pathway. Exemplary conditions, disorders, and diseases relevant to this disclosure include HIV infections, WHIM syndrome, Waldenström macroglobulinemia, chronic neutropenia, primary immune-deficiency, aplastic anemia, hypoplastic myelodysplastic syndrome, acute respiratory distress syndrome (ARDS), ankylosing spondylitis, autoimmune diseases, and cancers.
Absstract of: US20260345618A1
The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, Pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.
Absstract of: US20260345680A1
0000 Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM) targeting B-cell maturation antigen (BC-MA) induces high overall response rates. However, relapse occurs frequently and novel strategies for CAR-T cells targeting MM cells are needed. CAR-T cells targeting CD38 represent a potential alternative, but expression of CD38 on activated T cells and other hematopoietic cells raises concerns about the efficacy and safety of such therapy. Here, the inventors developed DCAR, a double CAR system targeting CD38 and SLAMF7 (CS1) through split activation and co-stimulation receptors, respectively. Furthermore, the inventors show that CRISPR/Cas9 inactivation of the CD38 gene enhances the anti-MM activity of DCAR-T in vitro. Edited DCAR-T developed strong responses specifically against MM cells expressing both the CD38 and the CS1 antigens in vitro and in vivo. Importantly, the inventors bring evidence that, unlike anti-CD38 CAR-T, which elicited a severe immune reaction against hematopoietic cells in a humanized mouse model, DCAR-T showed no sign of toxicity. Accordingly, the present invention relates to novel dual split CAR-T cells and uses thereof for the treatment of CD38-positive hematological malignancies.
Absstract of: US20260345647A1
0000 A treatment method, comprising using a drug containing AST-3424, AST-3423 or AST-2870 and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof in combination with a drug containing cytarabine or daunorubicin and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof to treat leukemia and lymphoma patients. Where the concentration of daunorubicin or cytarabine is far lower than the clinical dosage thereof, there is no need to limit patients to those with higher (overexpression, excess) AKR1C3 protein or RNA expression; the combination of AST-3424 and cytarabine or daunorubicin still has a remarkable inhibitory effect on the in-vitro proliferation of leukemia or lymphoma cells, and the combination has a relatively good inhibitory effect on the in-vitro proliferation of cell lines with different levels of AKR1C3 protein or RNA expression. Therefore, the described combination protocol is expected to be developed into a new treatment protocol for treating leukemia and lymphoma without limiting the level of AKR1C3 enzyme expression in patients.
Absstract of: US20260345683A1
0000 The present study of the regulatory T phenotype of Sézary cells led to the discovery of the overexpression of CD81 by Sézary cells. CD81 has also been shown to be a relevant therapeutic target in the treatment of Sézary syndrome, NK/T lymphoma, hepatosplenic T-cell lymphoma and acute T cell leukemia. CD81 therefore appears as a diagnostic marker and as a therapeutic target in T-cell malignancies. Accordingly, the present invention relates CD81 as a biomarker and biotarget in T-cell malignancies.
Absstract of: US20260347948A1
0000 Methods for treating and/or assessing a subject having a symptomatic multiple myeloma or a precursor thereof, where the methods involve characterizing a plasma cell dyscrasia (e.g., monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, multiple myeloma, plasma cell leukemia) in a biological sample from a subject as being high, medium, or low risk by assigning to the plasma cell dyscrasia a multiple myeloma (MM)-like score. The methods may involve sequencing DNA from the biological sample using whole-genome sequencing (WGS).
Absstract of: EP4834352A1
0001 The invention relates to a composition or a kit comprising a Toll-like receptor agonist and an Interleukin-7 (IL-7) antagonist as well as methods and uses for treating or preventing lymphoblastic leukemia.
Nº publicación: EP4834348A1 04/11/2026
Applicant:
PRIME GENE THERAPEUTICS CO LTD [CN]
Prime Gene Therapeutics Co., Ltd.
Absstract of: EP4834348A1
The present application relates to a pharmaceutical composition comprising an active ingredient Compound 1, a pharmaceutically acceptable polymeric carrier, a surfactant, and other pharmaceutically acceptable excipients; wherein said active ingredient, said polymeric carrier, and optionally at least a portion of said surfactant are present in the form of a solid dispersion. The present application discloses for the first time a pharmaceutical composition comprising Compound 1, which has stable product quality and good bioavailability. Based on the property of Compound 1 as a JAK inhibitor, the composition has broad application prospects for alopecia areata, vitiligo, atopic dermatitis, psoriasis, membranous nephropathy, ankylosing spondylitis, peripheral T-cell lymphoma, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, etc.
BOPI
Electronic site
